Literature DB >> 19830399

[Secondary prevention of stroke according to PRoFESS and SPARCL].

D Sander1, T Etgen.   

Abstract

Stroke is still the leading cause of long-term major disability in developed countries, although several improvements have been achieved in acute stroke therapy (e.g. thrombolysis, stroke-unit treatment,etc.). Therefore, an effective secondary prevention - guided by the etiology and risk factors of stroke - is of particular importance to reduce stroke morbidity. Recently, two important studies (SPARCL and PRoFESS) analyzed the significance of statin therapy as well as the efficacy of different antiplatelet therapies for secondary stroke prevention. In this review we summarize the results and discuss the implications of these findings - including the most recent data - for stroke prevention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830399     DOI: 10.1007/s00108-009-2471-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  51 in total

1.  Discontinuation of statin treatment in stroke patients.

Authors:  Matthias Endres; Ulrich Laufs
Journal:  Stroke       Date:  2006-08-31       Impact factor: 7.914

2.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

3.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

Review 5.  Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis.

Authors:  Pierre Amarenco; Julien Labreuche; Philippa Lavallée; Pierre-Jean Touboul
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

6.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Authors:  Deepak L Bhatt; Marcus D Flather; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Liz Fabry-Ribaudo; Tingfei Hu; Eric J Topol; Keith A A Fox
Journal:  J Am Coll Cardiol       Date:  2007-04-11       Impact factor: 24.094

7.  Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Authors:  Pierre Amarenco; Larry B Goldstein; Michael Szarek; Henrik Sillesen; Amy E Rudolph; Alfred Callahan; Michael Hennerici; Lisa Simunovic; Justin A Zivin; K Michael A Welch
Journal:  Stroke       Date:  2007-10-25       Impact factor: 7.914

8.  Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.

Authors:  Pierre Amarenco; Oscar Benavente; Larry B Goldstein; Alfred Callahan; Henrik Sillesen; Michael G Hennerici; Steve Gilbert; Amy E Rudolph; Lisa Simunovic; Justin A Zivin; K Michael A Welch
Journal:  Stroke       Date:  2009-02-19       Impact factor: 7.914

Review 9.  Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease.

Authors:  Mervyn D I Vergouwen; Rob J de Haan; Marinus Vermeulen; Yvo B W E M Roos
Journal:  Stroke       Date:  2008-01-03       Impact factor: 7.914

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

View more
  1 in total

Review 1.  [Carotid artery stenosis: current state of therapy].

Authors:  K I Schmidt; P Papanagiotou; A Zimmer; H-J Schäfers; W Reith
Journal:  Radiologe       Date:  2010-07       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.